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Abstract: The cone snails (family Conidae) are the best known and most intensively studied venomous
marine gastropods. However, of the total biodiversity of venomous marine mollusks (superfamily
Conoidea, >20,000 species), cone snails comprise a minor fraction. The venoms of the family
Drilliidae, a highly diversified family in Conoidea, have not previously been investigated. In this
report, we provide the first biochemical characterization of a component in a Drilliidae venom and
define a gene superfamily of venom peptides. A bioactive peptide, cdg14a, was purified from the
venom of Clavus davidgilmouri Fedosov and Puillandre, 2020. The peptide is small (23 amino acids),
disulfide-rich (4 cysteine residues) and belongs to the J-like drillipeptide gene superfamily. Other
members of this superfamily share a conserved signal sequence and the same arrangement of cysteine
residues in their predicted mature peptide sequences. The cdg14a peptide was chemically synthesized
in its bioactive form. It elicited scratching and hyperactivity, followed by a paw-thumping phenotype
in mice. Using the Constellation Pharmacology platform, the cdg14a drillipeptide was shown to cause
increased excitability in a majority of non-peptidergic nociceptors, but did not affect other subclasses
of dorsal root ganglion (DRG) neurons. This suggests that the cdg14a drillipeptide may be blocking a
specific molecular isoform of potassium channels. The potency and selectivity of this biochemically
characterized drillipeptide suggest that the venoms of the Drilliidae are a rich source of novel and
selective ligands for ion channels and other important signaling molecules in the nervous system.
Keywords: venom; Clavus; Drilliidae; drillipeptide
Key Contribution: We report the discovery and chemical characterization of a peptide isolated from
the drilliid gastropod, Clavus davidgilmouri.
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1. Introduction
The successful evolutionary radiation of the venomous marine snails in the superfamily Conoidea
has generated a significant fraction of the biodiversity of living mollusks (>20,000 species) [1,2].
Traditionally, three groups of gastropods, the cone snails, the auger snails, and the turrids, were thought
to comprise this superfamily. However, anatomical and molecular phylogenetic studies revealed
that while cone snails belong to a single monophyletic lineage (the family Conidae), and the auger
snails can similarly be grouped into a single clade (the family Terebridae), the conoidean snails that
have generally been referred to as turrids (the former family Turridae, sensu lato) comprise several
phylogenetically unrelated groups, some of which are more closely related to the cone snails than to
the type genus of the Turridae, Turris [3–5].
In a proposed reorganization of the superfamily Conoidea based on molecular data with the
most recent emendations [6], the members of the old family Turridae have been reclassified into
15 monophyletic families. One of the most diverse phylogenetic lineages of former “turrids” whose
distinctiveness has long since been acknowledged, is the family Drilliidae [1,6]. The venoms of this
species-rich conoidean family until recently remained completely uncharacterized, likely because
most drilliids are relatively small, uncommon, and predominantly collected offshore. Earlier this year,
results of the transcriptomic analysis of two species in the genus Clavus were published [7] featuring
unparalleled diversity of putative venom components in these gastropods. An important finding of
Lu et al. [7] was the high number of transcripts encoding short cysteine-rich mature peptides, sharing
some crucial structural features of conotoxins [8]. Such structural similarity suggests that drilliid venom
peptides are also likely to share some pharmacological properties of conotoxins. Taking into account
the broad interest in conotoxins, discovering a principally novel source of natural peptides with similar
bioactivity would be of great importance. However, first, the predicted transcripts need to be validated
by the analysis of venom proteins, and second, the proposed bioactivity has to be demonstrated.
In this report, we describe the purification and characterization of cdg14a, isolated from the
venom of Clavus davidgilmouri Fedosov and Puillandre, 2020, the first bioactive peptide of any species
in the family Drilliidae. Following Lu et al. [7], we refer to the venom peptides from species in this
family as “drillipeptides” to distinguish these from conopeptides and turripeptides. The species that
we have investigated, Clavus davidgilmouri, measures ~15–30 mm (Figure 1); it is one of the species in
the broadly distributed Indo-Pacific Clavus canalicularis complex, whose taxonomy has been recently
revised [9] and for which transcriptomic data is available [7].
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Figure 1. Shells of Clavus species. From left to right: Clavus davidgilmouri, Clavus canalicularis, Clavus 
viduus, Clavus unizonalis, and Clavus suduirauti [9–11]. 
Figure 1. Shells of Clavus species. From left to right: Clavus davidgilmouri, Clavus canalicularis,
Clavus viduus, Clavus unizonalis, and Clavus suduirauti [9–11].
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2. Results
2.1. Identification and Initial Characterization of Drillipeptide cdg14a
The chromatographic profile of the crude venom is shown in Figure 2A; bioactivity was detected
in the fraction indicated by the arrow in Figure 2A,B. This fraction caused a shaking phenotype in
mice, followed by scratching, excessive grooming, and hind feet tapping. This bioactivity was used
to guide the purification of the active component, and a high-performance liquid chromatography
(HPLC) profile of the purified venom drillipeptide is shown in Figure 2C.
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nm (black) and 280 nm (grey), with the elution gradient indicat d by a blue line. (A) Chromatogram
of the crude venom extract using a C18 semi-preparative column with linear gradient ranging from
6% to 60% solvent B (90% acetonitrile with 0.1% trifluoroacetic acid) at 0.9% solvent B/min, followed
by 60% to 100% at 1.3% solvent B/min. The peak f the bioactive fraction is indicated by an arrow.
(B) Chromatogram of the bioactive fraction reinjected in he HPLC using a C18 analytical column run
at a shal ower linear gradien ranging from 23% to 27% solvent B at 0.15% solvent B/min. The peak of
the subfraction containing the bioactive peptide cdg14a is indicated by an arrow. (C) Chromatogram of
the purified peptide cdg14a, showing a single, symmetrical peak.
The sequence of the analyzed peptide was deduced from the precursor sequence identified in the
transcriptome (Figure 3A); the apparently homogenous peptide was analyzed by mass spectrometry,
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and its peptide sequence (Figure 3B) matched the one predicted from transcriptome. The 23 AA peptide
has 4 Cys residues, in an arrangement similar to Framework XIV of conotoxins (—C—C—C—C—),
first characterized from peptides of the J-conopeptide superfamily [12]. We refer to this peptide as
cdg14a, belonging to the J-like drillipeptide superfamily (a nomenclature consistent with that proposed
for venom peptides from conoideans) [13].
Toxins 2020, 12, x FOR PEER REVIEW 4 of 15 
 
solvent B/min. The peak of the subfraction containing the bioactive peptide cdg14a is indicated by an 
arrow. (C) Chromatogram of the purified peptide cdg14a, showing a single, symmetrical peak. 
 
Figure 3. (A) CvDg14.4, cdg14a precursor sequence. Blue arrow indicates boundary between signal 
sequence and propeptide, black arrow between propeptide and mature toxin region, gray arrow 
between mature toxin and post-peptide region. Underlined residues denote recognition sites for 
predicted propeptide and post-peptide cleavage sites. The stop codon, denoted by an asterisk (*), is 
post-translationally modified to NH2, as shown in Figure 3B. (B) Peptide sequence of cdg14a. 
2.2. Characterization of the Precursor of cdg14a 
The encoded translation product has the organizational characteristics of conopeptide 
precursors (Figure 3A) comprising a signal sequence at the N-terminus, followed by a propeptide 
region, and the mature peptide region at the C-terminal end. The arrows indicate the boundaries 
between signal sequence and propeptide, as well as between the propeptide and the mature peptide 
region. A transcriptome analysis of two individual specimens [7] revealed at least nine related 
peptide precursors that share a highly conserved signal sequence (Figure 4), defining a gene 
superfamily, with all members found in Clavus davidgilmouri also sharing the same arrangement of 
Cys residues (Framework XIV) in the mature toxin region; the analysis also revealed the presence of 
a conserved glycine (Gly) in the third inter-cysteine loop. 
 
Figure 4. Clavus davidgilmouri complete precursor sequences related to cdg14A aligned with 
MUSCLE (MacVector 17.0) and refined by eye. These sequences belong to a single family of genes as 
indicated by their highly conserved N-terminal signal sequence (indicated in italics). Cysteines are 
highlighted in yellow and the conserved glycine in grey. Predicted precursor and post-peptide 
cleavage sites are underlined. Conserved amino acid residues are denoted by an asterisk (*) below 
the alignment. 
2.3. Chemical Synthesis of cdg14a 
In order to verify that the biochemically characterized peptide is indeed responsible for the 
activity detected in the venom fraction, cdg14a was chemically synthesized as described under the 
Methods section. The linear form of cdg14a was problematic to handle due to its low solubility; 
therefore, to increase its hydrophilicity, the cysteines of the peptide were temporarily modified 
using 2-aminoethyl methanethiosulfonate hydrobromide (MTSEA), a positively charged 
sulfhydryl-selective reagent that forms mixed disulfides with the cysteine residues [14]. Figure 5 
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C18 column before (Figure 5A) and after the MTSEA treatment (Figure 5B). This approach allowed 
us to obtain 3378 nmols of the linear, SEA-modified peptide (SEA, 2-aminoethanethiol) out of 108 
mg of the cleaved resin, with purity ranging from 64% to 81%. Electrospray Ionization (ESI) mass 
spectrometry analysis confirmed the identity of cdg14a-SEA: calculated (M) = 2574.92 Da; 
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Figure 4. Clavus davidgilmouri complete precursor sequences related to cdg14A aligned with MUSCLE
(MacVector 17.0) and refined by eye. These sequences belong to a single family of genes as indicated
by their highly conserved N-terminal signal sequence (indicated in italics). Cysteines are highlighted
in yellow and the conserved glycine in grey. Predicted precursor and post-peptide cleavage sites are
underlined. Conserved amino acid residues are denoted by an asterisk (*) below the alignment.
2.3. Chemical Synthesis of cdg14a
In order to verify that the biochemically characterized peptide is indeed responsible for the activity
detected in the venom fraction, cdg14a was chemically synthesized as described under the Methods
section. The linear form of cdg14a was problematic to handl du to its low solubility; therefore, to
increase its hydroph licity, the cysteines f the peptide wer temporarily modified using 2-aminoethyl
methanethio ulfonate ydrobromide (MTSEA), a po itively ch rged sulfhydryl-select ve reagent that
forms mixed disulfides with t e cysteine residu s [14]. Figure 5 illustrates profiles of the crude peptide
sol t on (the same volume and concentration) injected on the C18 column before (F gure 5A) and
after t e MTSEA treatm nt (Figure 5B). This approach allowed us o obtain 3378 nmols of the linear,
SEA-modified peptide (SEA, 2-aminoethanethiol) out of 108 mg of the cleaved resi , with purity
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ranging from 64% to 81%. Electrospray Ionization (ESI) mass spectrometry analysis confirmed the
identity of cdg14a-SEA: calculated (M) = 2574.92 Da; determined (M) = 2574.92 Da. This method was
recently successfully employed to obtain conopeptide AtVIA (V28L:T30S) [15].
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Figure 5. Chemical synthesis and folding of cdg14a. (A) HPLC chromatogram of a crude linear 
cdg14a eluted on an analytical C18 column using a gradient ranging from 5% to 65% solvent B in 30 
min with 1 mL/min flow rate. (B) HPLC chromatogram of a crude linear cdg14a modified with 
2-aminoethyl methanethiosulfonate hydrobromide (MTSEA) (HPLC conditions are the same as in 
panel A). (C) oxidative folding of cdg14a monitored by HPLC, using a C18 column and a gradient 
Figure 5. Chemical synthesis and folding of cdg14a. (A) HPLC chromatogram of a crude linear
cdg14a eluted on an analytical C18 column using a gradient ranging from 5% to 65% solvent B in
30 min with 1 mL/min flow rate. (B) HPLC chromatogram of a crude linear cdg14a modified with
2-aminoethyl methanethiosulfonate hydrobromide (MTSEA) (HPLC conditions are the same as in
panel A). (C) oxidative folding of cdg14a monitored by HPLC, using a C18 column and a gradient
ranging from 15% to 45% solvent B, with a flow rate 1 mL/min. Single asterisk denotes the native-like
fold of cdg14a. (D) zoom-in on 4 h oxidative folding time point (black HPLC trace) with all possible
folding isomers identified at 220 nm. The red trace represents the native folding isomer with the
globular-like connectivity Cys3-Cys15, Cys9-Cys20; green trace represents ribbon-like folding isomer
with the Cys3-Cys20, Cys9-Cys15 connectivity; blue trace represents the fast folding product with the
bead-like connectivity Cys3-Cys9, Cys15-Cys20. The traces were collected using the same gradient as
described for panel (C).
The linear cdg14a-SEA was then subjected to an oxidative folding reaction in the presence of a 1:1
mixture of reduced and oxidized glutathione in a buffered solution (pH = 7.5). Two-step transformation
was observed: a rapid folding step leading to a more hydrophobic isomer than the native peptide
(maximum accumulation of the product in the first 30 min of the reaction) and a slow reshuffling step
(in over 24 h) into the final product, with the same retention time of the native peptide (Figure 5C).
The significant difference in the retention times between both folding forms (6 min) suggests that
the peptide initially collapsed to an isomer with the hydrophobic residues exposed on its surface,
which then were moved toward its core during the long reshuffling process. Following the 24-h
folding protocol, cdg14a was obtained with 98% purity in 44% yield (based on the linear peptide used),
whereas the 30-min protocol led to the more hydrophobic isomer, cgd14a_pk2, in 26% yield and 95%
purity. MALDI mass spectrometry confirmed the identity of both peptides. For cdg14a, the major mass
determined, 2293.92 Da, was a sodium adduct, whereas the expected mass (M + H)+ = 2271.91 Da was
a minor signal (calculated (M + H)+ = 2271.84 Da). For cdg14a_pk2, an additional potassium adduct
was observed with a mass of 2309.87 Da.
The synthetic cdg14a peptide was obtained in the glutathione-assisted folding, and the native
peptide was subjected to the co-elution experiment, the results of which are illustrated in Figure 6.
Both peptides were first eluted individually (Figure 6A,B) and then as a mixture in 1:2 ratio (Figure 6C)
of the native to the synthetic peptide. The individual peaks had the same retention times, and the
mixed peak showed a uniform profile.
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Figure 6. Coelution profile of native and synthetic cdg14a. The HPLC runs were carried out using
an analytical C18 column and a gradient of 0.15% solvent B/min. (A) Native cdg14a isolated from
Clavus davidgilmouri venom. (B) Synthetic cdg14a. (C) Mixture of the native and synthetic samples (1:2)
of cdg14a.
To establish connectivity of the native peptide, an orthogonal protection of the cysteines and a
stepwise oxidative folding were employed. The globular (Cys3–15, Cys9–20), bead (Cys3–9, Cys15–20),
and ribbon (Cys3–20, Cys9–15) forms of cdg14a were synthesized following a two-step oxidative
folding: first in the presence of reduced and oxidized glutathione to form the first disulfide bridge,
followed by folding in the presence of iodine to facilitate the second disulfide bond formation. Based
on the co-elution experiments with the peptide obtained in a one-step, glutathione-assisted folding
experiment (which co-eluted with the native peptide) and the product of a two-step directed folding
(Figure S5, Supplementary Information), it was established that the native peptide has the globular
(Cys3–15, Cys9–20) fold, and the kinetically favored form, cdg14a_pk2, has the bead (Cys3–9, Cys15–20)
fold (Figure 5D). Both the bead and the ribbon forms were prone to precipitation from the solution,
and re-solubilization was not achieved, therefore inhibiting assessment of their bioactivity.
2.4. Behavioral Assay of cdg14a
The native peptide (~2 nmol) caused shaking in mice, which was followed by scratching, excessive
grooming, and foot tapping. When injected intracranially into mice, the synthetic cdg14a elicited
the same bioactivity as the native peptide at 2.5 nmol and higher. Because of the extremely limited
amounts of the native peptide, the synthetic peptide was used to characterize further the in vivo
biological activity.
The synthetic peptide elicited a series of distinctive behavior l phe otypes in mice in a sequential
combination not previously observed for any conopeptide; particularly noteworthy was the thumping
phenotype. At a dose of 2.5 nmol, the peptide elicited a shaking phenotype, scratching with the hind
paws, and excessive grooming; this was followed by a characteristic thumping of the hind paws.
The onset and duration of each symptom were depen ent on the dose (Table 1).
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Table 1. Effects of cdg14a on mice b.
Average Weight ± Deviation (g) nmol of cdg14a in NSS Observations (Intracranial Injection)
12.1 ± 0.1 0 No unusual behavior observed
10.4 ± 0.3 1 Mild shaking at 15 min;frequent scratching and grooming at 22 min lasting 2.5 h.
10.6 ± 0.1 2.5
Shaking at 7 min;
frequent scratching and grooming at 11 min;
licking of front paw and thumping of hind paw at 1 h lasting 2.5 h.
One mouse had convulsions at 3.5 h but recovered.
11.06 ± 0.26 5
Shaking, frequent scratching, and grooming at 7 min;
licking of front paw and thumping of hind paw at 18 min lasting 18 min;
seizure at 40 min; lying on its side for the rest of the experiment (>3 h).
11.6 ± 0.2 10
Shaking, frequent scratching, and grooming at 5 min;
licking of front paw and thumping of hind paw at 9 min lasting 18 min;
seizure at 37 min; lying on its side for the rest of the experiment.
Mice died at 2 h.
b Swiss Webster mice, n = 2 per dose, male and female; this table reflects data on synthetic cdg14a.
2.5. Constellation Pharmacology
Cdg14a induces aberrant behavior in mice upon intracranial injection suggesting that this
peptide is active in the murine central nervous system (CNS). We next determined whether the
peptide was also active in the peripheral nervous system (PNS). To achieve this goal, we performed
calcium imaging experiments on dissociated dorsal root ganglion (DRG) neurons harvested from
mice. The neuronal subclass affected by the peptide was determined by the response of neurons to the
following pharmacological agents: allyl isothiocyanate (TrpA1 agonist), menthol (TrpM8 agonist) and
capsaicin (TrpV1 agonist).
The application of synthetic cdg14a amplified the response of the cells to depolarization induced
by the application of 20 mM KCl (Figure 7). Interestingly, a significant effect of cdg14a is seen in a class
of small diameter neurons (<500 µm2) that are labeled by isolectin B4 (IB4), a plant lectin that binds the
carbohydrate moiety of glycoproteins and glycolipids. Further, this cell class responds to the transient
receptor Ankyrin 1 (TrpA1) agonist allyl isothiocyanate (AITC) and menthol, an agonist of the transient
receptor potential cation channel subfamily M (melastin) member 8 (TrpM8). Experiments on DRG
neurons harvested from four mice showed that 10 nM cdg14a induces a 76 ± 11% maximal response to
20 mM K+ in the presence of the peptide relative to control in this neuronal class.
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Figure 7. Constellation Pharmacology. The images starting from the left are taken using (1) the green
fluorescent (GFP) filter to visualize calcitonin gene related peptide (CGRP), (2) Cy5 filter to visualize
cells stained with isolectin B4 (IB4), (3) merged images of the GFP, Cy5 and brightfield channels, and (4)
the calcium imaging trace. Each calcium imaging trace corresponds to the response of a single cell to
the pharmacological challenge indicated on the X-axis at the bottom of panel C. The Y-axis indicates
the ratio of emission at 340/380 nm. The sizes of each cell are indicated on the right of each trace. The
pharmacological agents are as follows: allyl isothiocyanate (A), menthol (M) and capsaicin (C). Panel
(A) is cell class affected by cdg14a. These cells are small (<500 µm2), with strong IB4 staining, and
respond to allyl isothiocyanate, an agonist of the TrpA1 receptor and to menthol, an agonist of TrpM8.
The effects of cdg14a at different concentrations are seen as higher peak amplitude in pulses 4 to 5
relative to baseline responses in pulses 1 to 3. The mean response to 10 nM cdg is 76 ± 11%, increase in
peak height relative to the control. The K+ concentration in these pulses is 20 mM unless specified.
Panels (B,C) are classes of cells that are generally not affected by cdg14a. Cells in (B) are large cells
(>500 µm2) that show a direct response to the voltage-gated K+ channel inhibitor conotoxin κM-RIIIJ
(RIIIJ), while cells in (C) (>500 µm2) which are CGRP positive, have an indirect response to RIIIJ as
shown by a higher response to 20 mM K+ immediately after RIIIJ incubation.
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The activity observed in DRG neurons is similar to that of the voltage-gated potassium channel
(VGKC) blocker peptide cce9b from another conoidean, Crassispira cerithina [16], suggesting that, like
cce9b, cdg14a possibly inhibits a subset of VGKC by either direct or indirect inhibition of channel
activity. The spectrum of DRG neurons affected is unique and not observed with any other ligand
tested so far.
3. Discussion
This is the first report describing the characterization of any drilliid venom component.
We identified and characterized a bioactive peptide from the venom of Clavus davidgilmouri, cdg14a,
and defined a putative new gene superfamily, the J-like drillipeptides, comprising a diversity of venom
peptides structurally similar to cdg14a and only known from the species of Drilliidae. We confirmed
previous results of Lu et al. [7] that several different J-like drillipeptides are expressed in the venom
gland of Clavus davidgilmouri.
Like conopeptides, the drillipeptides are relatively small and rich in disulfides (4 Cys residues out
of 23AA in cdg14a). The organization of the J-like drillipeptide precursors is directly comparable to the
conopeptides—three well-defined regions can readily be identified: a signal sequence that is highly
conserved, a propeptide region, and a mature peptide region at the C-terminus (Figure 4). Although
they share the same Cys framework (Framework XIV, —C—C—C—C—), there appears to be little
sequence similarity between the J-conopeptide superfamily and the J-like drillipeptide superfamily.
The J-conopeptide superfamily precursor sequences obtained from the Conoserver database and those
of the J-like drillipeptide superfamily show 12.8–23.1% identity, whereas the pairwise identities are
53.8–79.5% among the J-conopeptide precursors and 76.7–93.3% among J-like drillipeptide precursors.
The J-like drillipeptides also show predicted C-terminal amidation in the mature peptide, a modification
that is fairly common in conopeptides, including the J superfamily.
The drillipeptide cdg14a was chemically synthesized, and the linear peptide was folded into
the native, biologically active conformation by oxidizing Cys residues to form disulfide bonds.
The oxidation of the linear cdg14a peptide is rather unprecedented, in that a bead intermediate (with
the cysteine connectivity 3–9, 15–20 different from the final one) is rapidly accumulated, followed by a
slow conversion to an oxidized peptide that has the native, globular disulfide framework (with the
cysteine connectivity 3–15, 9–20). This kinetically favored form elutes much later on a reverse-phase
HPLC column, suggesting that hydrophobic residues are exposed to the medium to a much greater
extent than in the native, biologically active peptide. The equilibration to the presumably lower energy
native disulfide-bonded peptide is rather slow, as shown in Figure 5, under the standard folding
conditions for conoidean venom peptides. Interestingly, the ribbon form of the peptide was also
identified in the folding solution, possibly being the second folding intermediate before reshuffling to
the native form (Figure 5D).
The isolated and characterized peptide, cdg14a, is novel in its biological activity. While the
shaking and hyperactivity phenotype have been reported in several conopeptides that target potassium
channels [17], calcium channels [18], and the neuronal noradrenaline receptor [19], the paw-thumping
phenotype elicited after intracranial injection has never been observed for any venom peptide.
Particularly striking as well is the sequence of behavioral phenotypes, which manifested at a
dose-dependent time period after injection of the peptide: the mice became hyperactive and then
exhibited the paw-thumping behavior. Since cdg14a was isolated from the venom of Clavus davidgilmouri,
named after Mr. David Gilmour, CBE, a member of the band Pink Floyd, and the thumping phenotype
was reminiscent of the Pink Floyd video featuring a long line of people thumping their feet, we refer to
this peptide as the “Pink Floyd” peptide.
The peptide has also been characterized using calcium imaging combined with a pharmacological
separation of different neuronal subtypes within the lumbar dorsal root ganglion of mice, a platform
called Constellation Pharmacology [20]. The results of the constellation pharmacology analysis revealed
that the peptide is surprisingly potent in mammalian systems, with nanomolar affinity for its targets.
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Furthermore, the cellular phenotypes observed are consistent with the highly selective inhibition of a
specific subset of potassium channels present in about 20% of all of the dorsal root ganglion neurons.
The non-peptidergic nociceptor neuronal population that does not express the CGRP peptide, and is
labeled by isolectin IB4, is one of the major classes of neurons affected. After the peptide is applied,
a greater increase in cytosolic (Ca)i is observed after a standard pulse of KCl—this is consistent with
the inhibition of a K+ channel present on the plasma membrane of these cells (although alternative
explanations, such as increased activity of Na+ channels, are also possible).
Thus, the first drillipeptide characterized appears to have a unique profile of bioactivity, both
at the whole animal behavioral level and at the cellular/molecular level. We are carrying out a more
thorough characterization, including a comprehensive structure/function analysis. Since the J-like
drillipeptide superfamily appears to be a rather large and diverse set of venom peptides within the
genus Clavus [7], these may contribute significantly to the characterization of native ion channels
present in different neurons. It has recently been established that different subclasses of neurons are
likely to express different complements of ion channel isoforms [20–23]. Understanding the function
and roles of these channels requires the availability of highly selective ligands for different ion channel
isoforms, making the discovery of novel natural ligands with high selectivity to channel isoforms a
high priority task. In this context, our finding that the J-like drillipeptide superfamily may provide
numerous novel ion channel-targeted peptides is of great importance.
4. Materials and Methods
4.1. Sample Collection
The specimens reported in this study and in the study of Fedosov and Puillandre, 2020 [9]
came from the same sample collection. Species identification was confirmed by Alexander Fedosov.
Forty-two live specimens of Clavus davidgilmouri were collected using tangle nets off Olango Island,
Cebu, the Philippines. The snails were dissected on ice, and venom ducts were collected. For the
transcriptome library assembly, 2 venom ducts were immediately suspended in RNAlater (Thermo
Fisher Scientific, Waltham, MA, USA) and stored at −20 ◦C until RNA extraction. The remaining
40 venom ducts were pooled in micro-centrifuge tubes and frozen in liquid nitrogen. Upon arrival in
the laboratory, venom ducts were transferred to and stored at −70 ◦C until venom peptide extraction.
Specimens were collected under the gratuitous permit no. 0111–16 issued by the Department of
Agriculture—Bureau of Fisheries and Aquatic Resources (DA-BFAR).
4.2. Venom Extraction and Purification
Venom ducts from Clavus davidgilmouri were thawed and re-suspended in 20% (v/v) acetonitrile
(CH3CN) with 0.2% (v/v) trifluoroacetic acid (TFA) and cut into smaller pieces. The mixture was
homogenized at 3000 RPM using a drill press and centrifuged at 15,000 RPM for 30 min. The supernatant
liquid was collected and kept at −70 ◦C, while a second extraction of the pellet was done using 40%
CH3CN with 0.2% TFA. The supernatants were pooled, diluted with 0.1% TFA, and applied to a
semi-preparative C18 high-performance liquid chromatography (HPLC) column (Phenomenex Jupiter,
Torrance, CA, USA; 250 × 10 mm, 10 µm particle diameter). The solvents were 0.1% TFA in water
(solvent A) and 90% CH3CN with 0.1% TFA in water (solvent B). Venom peptides were eluted from
the column with a linear gradient ranging from 6% to 60% solvent B at 0.9% solvent B/min, followed
by 60% to 100% at 1.3% solvent B/min. The flow rate was 3 mL/min and fractions were collected by
peak picking following the absorbance monitored at 220 and 280 nm. Subsequent fractionation of the
bioactive fraction was done using an analytical C18 HPLC column (Phenomenex Jupiter; 250 × 4.6 mm,
5 µm particle diameter) with a shallower linear gradient ranging from 23% to 27% solvent B at 0.15%
solvent B/min at 1 mL/min flow rate, until a single symmetrical peak was achieved.
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4.3. Peptide Characterization
Mass determination of the native peptides was accomplished by Electrospray Ionization (ESI)
Mass Spectrometry (MS) using Waters G2-XS quadrupole—time of flight (q-ToF) at the Institute of
Chemistry, University of the Philippines Diliman. Briefly, purified peptide fractions were injected
into a Waters 1.7 µm C18 column (50 × 2.1 mm) at a flow rate of 500 µL/min and eluted using a 5-min
gradient from 5% to 95% B (solvent A: 100% water with 0.1% formic acid; solvent B: 100% CH3CN
with 0.1% formic Acid). Data were acquired using the Fast Data Dependent Acquisition (FastDDA)
method with a selected mass range of 400–2000 m/z and a survey scan time of 0.4 s.
The amino acid sequence was determined by automated Edman degradation using Shimadzu
PPSQ-31B Protein Sequencer. Purified peptide fractions were loaded on a glass fiber disk pre-treated
with Sequa-brene™. Phenylisothiocyanate (PITC) was coupled to the amino group at the N-terminus
of the peptide in alkaline condition, producing a phenylthiocarbamyl (PTC) peptide. Trifluoroacetic
acid was used to cleave the peptide bond at the end of the PTC-peptide, producing the N-terminal
amino acid 2-anilino-5-thiazolinone (ATZ). The ATZ-amino acid was extracted with organic solvent
and converted to the more stable phenylthiohydantoin (PTH) derivative, and then separated using
reverse-phase HPLC. These reactions were repeated for multiple cycles until all amino acids of the
peptide were cleaved off. In each cycle, an unknown amino acid was identified by comparing HPLC
retention times to a previously analyzed PTH-amino acid standard.
4.4. Intracranial Mouse Bioassay
Aliquots of peptide fractions were dried, resuspended in 12 µL normal saline solution (NSS;
0.9% NaCl), and injected intracranially into 14- to 17-day-old mice using a 29-gauge insulin syringe.
Negative control mice were injected with NSS only. Mouse behavior after injection was observed for at
least three hours. This protocol is approved by the Institutional Animal Care and Use Committee of
the University of the Philippines Diliman (MSI-2014-01; approved 8 August 2014) and the University
of Utah (17-07020; approved 1 August 2017)
4.5. RNA Sequencing and Transcriptome Library Assembly
For whole transcriptome sequencing, total RNA extraction from venom glands of two specimens
of Clavus davidgilmouri was performed using the Direct-zol RNA extraction kit (Zymo Research,
Irvine, CA, USA), with on-column DNase treatment, according to the manufacturer’s instructions.
Transcriptome library preparation and sequencing were performed by the University of Utah High
Throughput Genomics Core Facility as previously described [24]. The raw reads data are available
as bioproject PRJNA610292. The analysis of transcriptomic data was carried out as described by
Lu et al. [7].
4.6. Putative Toxin Identification
Sequences from transcriptome were identified as potential toxin precursor peptides based on
the presence of a characteristic signal sequence, propeptide and toxin regions using website-based
computational servers SignalP 5.0 [25], Conoserver [26], and ProP 1.0 [27], classified into gene
superfamilies based on conserved sequences of the signal regions and further characterized by cysteine
framework. Putative toxin precursors were aligned with MUSCLE using MacVector 17.0 sequence
analysis software (MacVector, Inc., PO Box 1147, Apex, NC, USA) and refined by eye. The sequences
described here have been deposited into GenBank (Table S1).
4.7. Peptide Synthesis
Solid phase Fmoc peptide chemistry was used to generate cdg14a, cdg14 (3–9,15–20), cdg14
(3–15,9–20) and cdg14 (3–20,9–15) with an AAPPTec Apex 396 automated peptide synthesizer (Louisville,
KY, USA). The peptide, along with three additional analogs designed to establish disulfide connectivity
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of the native peptide, was initially constructed on a preloaded Fmoc-Rink Amide MBHA resin
(substitution: 0.45 mmol/g; Peptides International Inc., Louisville, KY, USA). All standard amino acids
were purchased from AAPPTec. Side-chain protection occurred for the following amino acids: Ser,
Thr and Tyr: O-tert-butyl, Cys: trityl (Trt), and Asp: tert-butyl. For cdg14 (3–9,15–20), Cys3 and Cys9
were protected with an acetamidomethyl (Acm) group and Cys15 and Cys20 with a trityl group; for
cdg14 (3–15,9–20) Cys3 and Cys15 were Acm protected while Cys9 and Cys15 were Trt protected;
whereas in cdg14 (3–20,9–15) Cys3 and Cys20 were Acm protected, and Cys9 and Cys15 were Trt
protected. The peptides were synthesized at 50 µmol scale. Coupling activation was achieved with
1 equivalent of 0.4 M benzotriazol-1-yl- oxytripyrrolidinophosphonium hexafluorophosphate and 2
equivalents of 2 M N,N-diisopropylethyl amine in N-methyl-2-pyrrolidone as the solvent. For each
coupling reaction, a 10-fold excess of amino acid was used, and the reaction was carried out for 60 min.
Fmoc deprotection was performed for 20 min with 20% (v/v) piperidine in dimethylformamide.
Peptide cleavage and purification were performed in the following manner. Linear cdg14a
was cleaved from 108 mg resin by a 2.5-h treatment with 1 mL of Reagent K
(TFA/water/phenol/thioanisole/1,2-ethanedithiol 82.5/5/5/5/2.5 by volume). Next, the cleavage mixture
was filtered and precipitated with 10 mL of cold methyl-tert-butyl ether (MTBE). The crude peptide
was then precipitated by centrifugation at 7000× g for 6 min and washed once with 10 mL cold MTBE.
Because of the poor solubility of the crude linear peptide, it was first treated with positively charged
2-Aminoethyl methanethiosulfonate hydrobromide (MTSEA; Biotium, Fremont, CA, USA) in order to
temporarily modify all cysteines and increase peptide hydrophilicity. Crude peptide was re-suspended
in 50% CH3CN in 0.1% TFA in water; then 50 mg of MTSEA was added. The reaction mixture was
vortexed and left for 1 h at room temperature. It was then diluted with 0.1% TFA in water and purified
by reversed-phase (RP) HPLC using a semi-preparative C4 Vydac column (204TP510, 250 × 10 mm,
5-µm particle size) eluted with a linear gradient ranging from 15% to 45% solvent B in 30 min at a flow
rate 4 mL/min. The HPLC solvents were 0.1% (v/v) TFA in water (solvent A) and 0.1% TFA (v/v) in
90% aqueous CH3CN (v/v) (solvent B). The eluent was monitored by measuring absorbance at 220
and 280 nm. The purity of the peptide was assessed by analytical C18 Vydac RP-HPLC (218TP54,
250 × 4.6 mm, 5-µm particle size) using the same gradient as described above with a flow rate of
1 mL/min. The peptide was quantified by UV absorbance at 280 nm, using an extinction coefficient
(ε) value of 4470 M−1·cm−1. The identity of the peptide was confirmed by ESI-MSI (calculated (M) =
2574.92 Da; determined (M) = 2574.92 Da) at the Mass Spectrometry and Proteomics Core Facility at
the University of Utah.
The same method of linear peptide modification was used for cdg14 (3–9,15–20), cdg14 (3–15,9–20)
and cdg14 (3–20,9–15) The bis-aminoethanethiol modified peptides were obtained on average in
62–85% purity, and identity was confirmed by ESI MS. The mass found was (M) = 2566.98 Da
(calculated (M) = 2566.99 Da).
4.8. Oxidative Folding of cdg14a in the Presence of Oxidized and Reduced Glutathione
Two hundred nanomoles of linear cdg14a was resuspended in 1 mL of 50% CH3CN in 0.01%
TFA solution and added to a solution containing the following: 5 mL of 0.2 M Tris-HCl (pH = 7.5)
plus 0.2 mM EDTA, 0.5 mL of 20 mM reduced and 0.5 mL of 20 mM oxidized glutathione, and 3 mL
of water. Final peptide concentration in the folding mixture was 20 µM. The folding reaction was
conducted for 24 h to obtain the native-like peptide cdg14a and 30 min to obtain the more hydrophobic,
kinetically favorable form cdg14a-pk2, then quenched with formic acid to a final concentration of 8%.
The quenched reaction mixture was then separated by RP-HPLC using a semi-preparative C18 column
and a linear gradient ranging from 15% to 45% of solvent B in 30 min with a flow rate of 4 mL/min.
The eluent was monitored by absorbance at 220 and 280 nm. The purity of the folded peptide was
assessed by an analytical C18 Vydac RP-HPLC using the gradient described for the linear peptide, with
a flow rate of 1 mL/min. Pure, fully folded cdg14a and cdg14a-pk2 were quantified by absorbance at
280 nm as described for the linear peptide. Out of 2000 nmols of linear peptide, 880 nmols of cdg14a
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were obtained with 98% purity (44% yield), and out of 745 nmols, 192 nmols of the more hydrophobic
isomer, cgd14a_pk2, were produced with 95% purity (26% yield). The molecular mass of cdg14a and
cdg14a_pk2 was confirmed by MALDI MS at Mass Spectrometry and Proteomics Core Facility at the
University of Utah. For cdg14a, the major mass determined was a sodium adduct 2293.92 Da, where
the expected mass (M + H)+ = 2271.91 Da was a minor signal (calculated (M + H)+ = 2271.84 Da). For
cdg14a_pk2, an additional potassium adduct was also observed with a mass of 2309.87 Da.
The same method of oxidative folding was used to close the first bridge in cdg14 (3–9,15–20),
cdg14 (3–15,9–20) and cdg14 (3–20,9–15) with the average yield of 46% and purity ranging between
87% and 92%. The identity of the peptides was confirmed by MALDI MS. The major mass observed
was identified to be a sodium adduct (M+ Na)+ = 2438.02 Da (calculated (M + Na)+ = 2437.92 Da)
and the minor to be a potassium adduct for all 3 folding isomers (M + K)+ = 2453.89 Da (calculated
(M + K)+ = 2454.02 Da).
Oxidative folding of cdg14 (3–9,15–20), cdg14 (3–15,9–20) and cdg14 (3–20,9–15) was performed
in the presence of iodine. In brief, 10 mg of iodine was dissolved in 5 mL of CH3CN, and 15 mL of
water and 0.6 mL of TFA were added. A total of 168 nmol of monocyclic, cdg14 (3–15,9–20) in 5 mL of
HPLC solvents was added to 5 mL of the iodine solution, and the reaction was stirred for 10 min. Then
it was quenched with 100 µL of freshly prepared 1 M ascorbic acid in water. The reaction was diluted
to 16 mL with solvent A and purified by RP-HPLC using a semi-preparative C18 column and a linear
gradient ranging from 15% to 45% of solvent B in 30 min with a flow rate of 4 mL/min. Pure, fully
folded cdg14 (3–15,9–20) was quantified by absorbance at 280 nm as described for the linear peptide to
yield 112 nmol of the fully folded peptide (yield: 65%, purity: 97%; tR = 16.07 min). The identity of the
peptide was confirmed by MALDI MS. The major mass determined was a sodium adduct (M + Na)+ =
2293.93 Da (calculated: 2293.82) and potassium adduct (M + K)+ = 2309.91 Da (calculated: 2309.88 Da),
where the expected mass (M + H)+ = 2271.93 Da was a minor signal (calculated (M + H)+ = 2271.84).
The same protocol was applied to prepare the bead analog cdg14 (3–9,15–20) (yield: 82%; purity: 95%
tR = 22.92 min) and ribbon analog cdg14 (3–20,9–15)(yield: ~20% (due to precipitation); purity: 95%;
tR = 20.51 min).
4.9. Co-Elution of the Native and Synthetic cdg14a
To determine whether the native and synthetic cgd14a peptides were identical, both peptides
were loaded separately on a C18 analytical column with a linear gradient of 20–23% of solvent B in
20 min at 1 mL/min to compare their retention times. A co-elution experiment was also done by mixing
native and synthetic cdg14a peptides in a 1:2 ratio and loaded on a C18 analytical column using the
same gradient.
4.10. Constellation Pharmacology
Experiments involving the use of live animals were approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of Utah (17-05017; approved 31 May 2017). Dorsal
root ganglia (DRG) were dissected from 6- to 8-week old CD1 mice engineered to express the green
fluorescent protein (GFP) under the control of the calcitonin gene related peptide (CGRP) promoter, thus
GFP was used for labeling CGRP-positive cells. DRGs were dissociated, plated on poly D-lysine-coated
24-well plates, and cultured overnight in minimum essential media (MEM) containing 10% FBS,
100 U/mL penicillin, 100 µg/mL streptomycin, 1× glutamax, 0.4% (w/v) glucose, and 10 mM HEPES
in a humidified incubator at 37 ◦C and 5% CO2. The cells were loaded with FURA-2-AM dye one
hour before the experiment. The cells were then washed 3× with DRG observation solution (145 mM
NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 1 mM Na-Citrate, 10 mM HEPES, 10 mM glucose and 1×
Pen-Strep) and allowed to recover for 10 min before the experiment was started. The ability of cdg14a
to modulate calcium transients in response to the application of 20 mM K+ was measured. Three pulses
of 20 mM K+ each for 10 s were applied to the DRG neurons at 6-min intervals. The neurons were
washed with DRG observation solution 3× after each K+ pulse. After the third K+ pulse, the neurons
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were incubated with 10 nM cdg14a for 5 min; then a solution containing 20 mM K+ plus 10 nM cdg14a
was applied to the cells for 10 s. The cells were again washed 3× with a DRG observation solution and
incubated with 100 nM cdg14a for 5 min. After 5 min, a solution of 20 mM K+ plus 100 nM cdg14a was
again applied to the neurons for 10 s. The cells were allowed to recover for 12 min, and then 20 mM
K+ was applied to determine the reversibility of the cdg14a effect. The cells were then incubated for
5 min in a DRG observation solution containing 1 µM of the conopeptide κM-RIIIJ to identify cells
expressing Kv1.1 and/or Kv1.2 [28]. Direct response to κM-RIIIJ, as well as response to 20 mM K+
after κM-RIIIJ incubation, indicating an indirect response, characterizes classes of DRG neurons [4].
The cells were then incubated for 15 s at 6-min intervals with the following: AITC (100 µM), menthol
(400 µM), capsaicin (300 nM), and K+ (40 mM). IB4 and HOECHST staining were performed after
calcium imaging experiments. Then a GFP image to visualize CGRP positive cells, a Cy5 image to
visualize IB4 positive cells, and a bright-field image were taken after the calcium imaging experiment.
Responses to the challenge compounds and the characteristic IB4 and CGRP labeling were used to
group cells into different subclasses [20]. Estimates of amplification resulting from 10 nM cdg14a
application are reported as mean ± SE. Means are computed as % maximal response to 20 mM K+ in
the presence of cdg14a relative to 20 mM K+ response in the absence of the peptide.
Supplementary Materials: The following additional materials are available online at http://www.mdpi.com/2072-
6651/12/8/508/s1, Table S1: List of GenBank Accession Numbers for CvDg peptide precursor sequences, Table S2:
Complete census of subclasses of cells showing a response to cdg14a. Values represent percent of all the cells in
each class that respond to cdg14a, Figure S1: Edman sequencing of cdg14a. Reliable reads were obtained only until
21 cycles, Figure S2: Mass spectrum of native cdg14a and calculated mass, Figure S3: Mass spectrum of reduced
(dithiothreitol) and alkylated (iodoacetamide) cdg14a and calculated mass, Figure S4: MS/MS fragmentation
spectrum of reduced and alkylated cdg14a, Figure S5: Co-elution experiment of the globular and bead forms
prepared in one and two step folding. Video S1: Foot thumping phenotype observed in young mice when injected
with cdg14a. Video S2: Negative control mouse.
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